Industry News

Acute Insomnia Cases to Increase at 0.71% Annually

Published on

Epidemiologists forecast that the total prevalent cases of acute insomnia in the 7 major markets (7MM) will increase from 121,799,911 in 2013, to 130,482,156 in 2023 at an Annual Growth Rate (AGR) of 0.71%. This is according to ReportsnReports.com new EpiCast Report: Insomnia – Epidemiology Forecast to 2023, which provides an overview of the risk factors, comorbidities, and the global and historical trends for insomnia in the 7MM.

GlobalData epidemiologists forecast an increase in the total prevalent cases of chronic insomnia (not fulfilling DSM-IV criteria) in the 7MM from 62,982,390 total prevalent cases in 2013, to 67,471,957 total prevalent cases in 2023 at an AGR of 0.71%. The 7MM had an estimated 23,690,040 total prevalent cases of chronic primary insomnia in 2013 and the number of total prevalent cases is expected to increase to 25,378,728 by 2023, at an AGR of 0.71%. GlobalData epidemiologists forecast that the total prevalent cases of chronic secondary insomnia in the 7MM will increase from 53,697,425 total prevalent cases in 2013, to 57,525,122 total prevalent cases in 2023 at an AGR of 0.71%.

Epidemiologists used comprehensive country-specific data from population-based studies published in peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the total prevalent cases of acute insomnia, chronic insomnia (not fulfilling DSM-IV criteria), chronic primary insomnia, and chronic secondary insomnia in the 7MM, based on the DSM-IV criteria. For all the 7MM, the total prevalent cases of acute insomnia, chronic insomnia (not fulfilling DSM-IV criteria), chronic primary insomnia, and chronic secondary insomnia were segmented by age and sex, which facilitates an understanding of the distribution of the disease within the population and informs strategies to improve the management of the disease. Furthermore, the forecast methodology is consistent across each of the 7MM, thereby allowing for a meaningful comparison of the forecast total prevalent cases among each market.